Coherus BioSciences Inc. (CHRS) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
C/O DENNIS M. LANFEAR REDWOOD CITY, CA 94065 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 117,748 | 191,681 | 417,195 | 541,200 | 177,668 | 72,356 | |||
| Cash and cash equivalents | 102,891 | 63,547 | 417,195 | 541,158 | 177,668 | 72,356 | |||
| Short-term investments | 14,857 | 128,134 | |||||||
| Other undisclosed cash, cash equivalents, and short-term investments | 42 | ||||||||
| Restricted cash and investments | 50 | ||||||||
| Receivables | 260,522 | 109,964 | 123,022 | 157,046 | 141,992 | ||||
| Inventory, net of allowances, customer advances and progress billings | 62,605 | 38,791 | 37,642 | 44,233 | 9,807 | 1,659 | |||
| Inventory | 62,605 | 38,791 | 37,642 | 44,233 | 9,807 | 1,659 | |||
| Prepaid expense | 2,379 | ||||||||
| Other current assets | 83 | ||||||||
| Other undisclosed current assets | 34,756 | 40,798 | 24,464 | 25,000 | 13,542 | 7,906 | |||
| Total current assets: | 475,631 | 381,234 | 602,323 | 767,479 | 343,009 | 84,433 | |||
| Noncurrent Assets | |||||||||
| Inventory, Noncurrent | 67,495 | 76,260 | 55,610 | 47,956 | 45,264 | 4,012 | |||
| Finance lease, right-of-use asset, after accumulated amortization | 1,451 | ✕ | |||||||
| Operating lease, right-of-use asset | 9,956 | 10,649 | ✕ | ||||||
| Property, plant and equipment | 5,119 | 8,754 | 7,813 | 5,840 | 6,660 | ||||
| Intangible assets, net (including goodwill) | 943 | 5,931 | 3,563 | 3,563 | 3,563 | 3,563 | |||
| Goodwill | 943 | 943 | 943 | 943 | 943 | ||||
| Intangible assets, net (excluding goodwill) | 5,931 | 2,620 | 2,620 | 2,620 | 2,620 | ||||
| Restricted cash and investments | 440 | 240 | 785 | ||||||
| Other noncurrent assets | 9,686 | 8,668 | 10,025 | 2,147 | 362 | 14 | |||
| Other undisclosed noncurrent assets | 70,730 | 8,657 | |||||||
| Total noncurrent assets: | 153,973 | 99,613 | 77,011 | 74,170 | 65,918 | 15,034 | |||
| TOTAL ASSETS: | 629,604 | 480,847 | 679,334 | 841,649 | 408,927 | 99,467 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 140,605 | 61,623 | 86,300 | 60,263 | 61,653 | 32,842 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 22,014 | 22,244 | 18,410 | 10,540 | ||
| Accounts payable | 35,219 | 11,526 | 16,159 | 15,201 | 25,985 | 15,294 | |||
| Accrued liabilities | 105,386 | 50,097 | 48,127 | 22,818 | 17,258 | 7,008 | |||
| Debt | 721 | 1,191 | 741 | 560 | 2,196 | ||||
| Derivative instruments and hedges, liabilities | |||||||||
| Estimated litigation liability | 4,700 | ||||||||
| Other liabilities | 3,861 | 2,196 | 419 | ||||||
| Other undisclosed current liabilities | 190,445 | 71,180 | 78,286 | 80,969 | 48,924 | ||||
| Total current liabilities: | 331,771 | 138,694 | 165,327 | 145,653 | 114,969 | 33,261 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 227,239 | 226,993 | 388,411 | 387,343 | 162,461 | 77,319 | |||
| Long-term debt, excluding current maturities | 226,888 | 225,575 | 381,160 | 377,395 | 152,205 | 77,319 | |||
| Finance lease, liability | 351 | 1,418 | 498 | 875 | ✕ | ||||
| Liabilities, other than long-term debt | 17,538 | 7,095 | 27,870 | 27,679 | 26,283 | 27,478 | |||
| Deferred income tax liabilities | ✕ | ||||||||
| Due to related parties | ✕ | ✕ | 27,120 | 26,628 | 26,181 | 25,773 | |||
| Other liabilities | 12,561 | 3,467 | 750 | 949 | 1,645 | ||||
| Operating lease, liability | 4,977 | 3,628 | 6,753 | 9,073 | 10,256 | ✕ | |||
| Business combination, contingent consideration, liability | 102 | 102 | 60 | ||||||
| Other undisclosed noncurrent liabilities | 246,481 | 245,483 | |||||||
| Total noncurrent liabilities: | 491,258 | 479,571 | 416,281 | 415,022 | 188,744 | 104,797 | |||
| Total liabilities: | 823,029 | 618,265 | 581,608 | 560,675 | 303,713 | 138,058 | |||
| Equity | |||||||||
| Equity, attributable to parent | (193,425) | (137,418) | 97,726 | 280,974 | 105,214 | (38,591) | |||
| Common stock | 11 | 8 | 7 | 7 | 7 | 7 | |||
| Additional paid in capital | 1,386,312 | 1,204,431 | 1,147,843 | 1,043,991 | 1,000,763 | 946,515 | |||
| Accumulated other comprehensive loss | (248) | (249) | (270) | (270) | (558) | (282) | |||
| Accumulated deficit | (1,579,500) | (1,341,608) | (1,049,854) | (762,754) | (894,998) | (984,831) | |||
| Total equity: | (193,425) | (137,418) | 97,726 | 280,974 | 105,214 | (38,591) | |||
| TOTAL LIABILITIES AND EQUITY: | 629,604 | 480,847 | 679,334 | 841,649 | 408,927 | 99,467 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 257,244 | 211,042 | 326,551 | 475,824 | 356,071 | |||
| Cost of revenue (Cost of Goods and Services Sold) | (158,992) | (70,083) | (57,591) | (37,667) | (410) | |||
| Gross profit: | 98,252 | 140,959 | 268,960 | 438,157 | 355,661 | |||
| Operating expenses | (301,451) | (397,839) | (532,818) | (281,838) | (248,303) | (204,416) | ||
| Other undisclosed operating income | 410 | |||||||
| Operating income (loss): | (203,199) | (256,880) | (263,858) | 156,319 | 107,768 | (204,416) | ||
| Nonoperating income (expense) | 5,469 | 3,822 | (283) | 821 | 2,847 | 4,691 | ||
| Investment income, nonoperating | 600 | |||||||
| Gain (loss), foreign currency transaction, before tax | (333) | 239 | ||||||
| Other nonoperating income (expense) | 5,469 | 3,822 | (283) | 554 | 2,608 | 4,691 | ||
| Interest and debt expense | (40,542) | (38,696) | (22,959) | (21,166) | (17,601) | (9,684) | ||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (267) | (240) | ||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (238,272) | (291,754) | (287,100) | 135,707 | 92,774 | (209,409) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 1 | |||||||
| Income (loss) from continuing operations before income taxes: | (238,272) | (291,754) | (287,100) | 135,707 | 92,775 | (209,409) | ||
| Income tax expense (benefit) | 380 | (3,463) | (2,942) | |||||
| Income (loss) from continuing operations: | (237,892) | (291,754) | (287,100) | 132,244 | 89,833 | (209,409) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (287,100) | 132,244 | 89,833 | (209,409) | |
| Net income (loss): | (237,892) | (291,754) | (287,100) | 132,244 | 89,833 | (209,409) | ||
| Net income attributable to noncontrolling interest | 70 | |||||||
| Net income (loss) available to common stockholders, basic: | (237,892) | (291,754) | (287,100) | 132,244 | 89,833 | (209,339) | ||
| Interest on convertible debt | ||||||||
| Net income (loss) available to common stockholders, diluted: | (237,892) | (291,754) | (287,100) | 132,244 | 89,833 | (209,339) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (237,892) | (291,754) | (287,100) | 132,244 | 89,833 | (209,409) | ||
| Other comprehensive income (loss) | 1 | 21 | ||||||
| Other undisclosed comprehensive income (loss) | 288 | (276) | 468 | |||||
| Comprehensive income (loss): | (237,891) | (291,733) | (287,100) | 132,532 | 89,557 | (208,941) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 70 | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (237,891) | (291,733) | (287,100) | 132,532 | 89,557 | (208,871) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.